Marijana Pavlovic

Dr. Marijana Pavlovic


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Cancer Biology & Medicine
Verified
Journal Article
Open access
PDF file
Jelena GrahovacJelena Grahovac
Jelena Grahovac
TSTatjana Srdic-Rajic
Tatjana Srdic-Rajic
FJFrancisco Santibañez Juan
Francisco Santibañez Juan
MPMarijana Pavlovic
Marijana Pavlovic
MCMilena Cavic
Milena Cavic
RSRadulović Siniša
Radulović Siniša
Telmisartan induces melanoma cell apoptosis and synergizes with vemurafenib in vitro by altering cell bioenergetics

1 September 2020 in Journal of Inorganic Biochemistry
Verified
Journal Article
Closed access
MPMarijana Pavlovic
Marijana Pavlovic
ATAna Tadić
Ana Tadić
NGNevenka Gligorijević
Nevenka Gligorijević
JPJelena Poljarević
Jelena Poljarević
TPTamara Petrović
Tamara Petrović
SASandra Aranđelović
Sandra Aranđelović

21 December 2020 in Expert Review of Molecular Diagnostics
Verified
Journal Article
Closed access
MCMilena Cavic
Milena Cavic
AKAna Krivokuca
Ana Krivokuca
IBIvana Boljevic
Ivana Boljevic
JSJelena Spasic
Jelena Spasic
MMMilica Mihajlovic
Milica Mihajlovic
RJRadmila Jankovic
Radmila Jankovic
Background: The SARS-CoV-2 pandemic introduced a global distraction effect in all aspects of cancer patients’ care. The aim of this study was to explore the effect of the pandemic on the largest molecular diagnostics center for cancer patients and high-risk individuals in Serbia. Research design and methods: EGFR, KRAS/NRAS, BRAF and BRCA1/2 mutation testing were performed by qPCR and NGS. NGS was used for panel testing of hereditary breast/ovarian cancer and cancers associated with Lynch syndrome. The analytical output during the state of emergency (SoE) was compared to the period before and after the outbreak using one-way ANOVA. Statistical significance was set at p<0.05. Results: A 38% reduction in the number of analysis was detected during the SoE. After the SoE, a 19% reduction was noted compared to SoE and 50% compared to the period before the SoE (p=0.038). Only 3 of the 48 scheduled appointments for pre-test genetic counseling were carried out during the SoE, but the number of NGS tests increased by 50%. Conclusions: The SARS-CoV-2 pandemic had a profound negative effect on the diagnostic output of our centralized molecular diagnostics center. The only positive effect was shortening of waiting lists for hereditary cancer patients and high-risk individuals.

14 February 2019 in JBIC Journal of Biological Inorganic Chemistry
Verified
Journal Article
Closed access
PDF file
MPMarijana Pavlovic
Marijana Pavlovic
SNStefan Nikolić
Stefan Nikolić
NGNevenka Gligorijević
Nevenka Gligorijević
BDBiljana Dojcinovic
Biljana Dojcinovic
SASandra Arandelovic
Sandra Arandelovic
SRSiniša Radulović
Siniša Radulović

31 August 2023 in Translational Oncology
Verified
Journal Article
Open access
MVMiodrag Vukovic
Miodrag Vukovic
MTMiljana Tanić
Miljana Tanić
Ana DamjanovicAna Damjanovic
Ana Damjanovic
MPMarijana Pavlovic
Marijana Pavlovic
ASAleksandra Stanojevic
Aleksandra Stanojevic
MCMilena Cavic
Milena Cavic
The use tumor-derived cell-free DNA extracted from body fluids is being evaluated for genetic testing in lung cancer. The aim of this study was to explore the feasibility and utility of implementation of EGFR molecular testing from pleural effusions in non-small cell lung cancer in the clinical diagnostics workflow. This study included patients diagnosed with primary lung adenocarcinoma in the period July 2016 to June 2023. EGFR mutation testing was performed by qPCR (Cobas®) and dPCR. Testing was performed from 211 plasma samples when tissue was unavailable at diagnosis, and from 301 plasma samples and 18 pleural effusions at progression on first/second generation of EGFR TKIs. Descriptive methods of statistical analysis were used to summarize the sample data. Fisher's exact test, McNemar's test, Cohen's kappa tests were used for statistical analyses. Two-sided p-values <0.05 were considered statistically significant. A significantly higher detection rate of the T790M mutation in pleural effusion was obtained compared to blood (50% and 20%, p=0.047). When comparing the detection success rate of the resistant T790M mutation in pleural effusion and blood, a statistically significant difference was obtained in favor of pleural effusion (50% vs. 21.87%, p=0.01). Superior performance of pleural effusions compared to blood plasma was shown both in the analysis of success rate and in the detection of the resistant T790M mutation, at progression on EGFR TKIs. Pleural effusion should be considered in this setting whenever available, especially in countries with limited health resources.

1 October 2019 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
JSJelena Spasic
Jelena Spasic
AKA. Krivokuca
A. Krivokuca
IBI. Boljevic
I. Boljevic
MPMarijana Pavlovic
Marijana Pavlovic
JRJ. Rakobradovic
J. Rakobradovic
MCMilena Cavic
Milena Cavic